The American horseshoe crab (Limulus polyphemus), a marine member of the Phylum Arthropoda is a popular hands-on exhibit animal in aquariums and zoological parks. At Ripley s Aquarium of the Smokies, white, proliferative, irregularly expansile lesions were observed on the soft tissue of the gills and the joint spaces of the legs and tails of crabs kept in a hands-on tank. Additionally, 1–2 mm diameter, circular, discolored red-brown, ulcerated lesions of the ventral carapace were recognized. A fungal etiology of the lesions was determined by cytology and histopathology. Itraconazole is a triazole anti-fungal agent and is widely used in human and veterinary medicine for the treatment of fungal infections. Pharmacokinetic studies are scarce for invertebrates (Gore et al., 2005), and those involving anti-fungal agents are lacking. This study was designed to determine the pharmacokinetics of itraconazole for the treatment of susceptible fungal infections in American horseshoe crabs. The study group consisted of 10 horseshoe crabs (six males and four females) equally divided into two 150 gallon recirculating tanks. Water quality parameters were assessed regularly, including temperature (23–25 C), pH (7.77–8.31), salinity (33–38 ppt), total ammonia ⁄NH3 ⁄NH4 -N (0.0 mg ⁄L), nitrite (0.02–0.05 ppm), nitrate (98–104 ppm), dissolved oxygen saturation (71–97.8%), dissolved oxygen (4.0–6.2 ppm), copper (0.003–0.009 ppm), and alkalinity ⁄CaCO3 (290–400 ppm). Sample collection and drug administration were performed through the cardiac sinus with the animal restrained in ventral flexion (Smith, 2006). A pilot study was conducted in one animal to establish a dose and sampling interval for itraconazole. The animal was given 5 mg ⁄kg i.v. itraconazole (Sporanox; Ortho Biotech, L.P., Raritan, NJ, USA) diluted with 0.9% sodium chloride to a concentration of 3.33 mg ⁄mL per manufacturer s instructions. This mixture was further diluted to 2 mg ⁄mL with 0.9% sodium chloride (Hospira, Lake Forest, IL, USA) to attain a pH of 6.60 as determined by Beckman F pH meter (Beckman Instruments, Inc., Irvine, CA, USA). Hemolymph was collected in a 3-mL syringe with a 22-guage needle at 0, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 72 h following itraconazole administration. The sample volume was 0.3 mL for a total of 3.3 mL hemolymph collected over the sampling period. Hemolymph was placed immediately in a lithium heparin microtainer (Becton Dickinson, Franklin Lakes, NJ, USA), centrifuged, and the hemolymph supernatant was placed in a cryovial and stored at )80 C until analysis. Based on the results from the pilot study, a dose of 10 mg ⁄kg was established for the full study. Procedures for itraconazole preparation, sample collection and handling were identical to those used in the pilot study. One untreated animal in the tank served as a negative control to assess the redistribution of itraconazole circulating in the water. Analyses for itraconazole, and its active metabolite, hydroxyitraconazole were performed using a modified HPLC method as previously described (Cox et al., 1997). Hemolymph samples were analyzed by reverse phase HPLC with fluorescence detection. The HPLC system consisted of a 2996 separations module, a 2475 fluorescence detector and a computer equipped with EMPOWER software (Waters, Milford, MA, USA). Standard curves for hemolymph analysis were prepared by fortifying untreated hemolymph with itraconazole and hydroxyitraconazole to produce a linear concentration range of 10– 5000 ng ⁄mL. The intra-assay variability for itraconazole ranged from 0.6% to 1.8% and 0.9% to 4.2% for the hydroxy metabolite. Inter-assay variability ranged from 0.5% to 10% for itraconazole and 1.8% to 9.2% for the hydroxy metabolite. Recovery ranged from 86% to 93% for itraconazole and 79% to 90% for hydroxyitraconazole. Analysis of concentration–time data and estimation of pharmacokinetic parameter values for itraconazole and its metabolite J. vet. Pharmacol. Therap. 31, 83–86, doi: 10.1111/j.1365-2885.2007.00924.x. SHORT COMMUNICATION
Read full abstract